Company H. Lundbeck A/S

HLUN B

DK0061804770

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 09:50:00 06/03/2026 pm IST			5-day change	1st Jan Change
37.78 ^DKK	-1.51%		-1.56%	-12.47%

05/03	Nordea Resumes Coverage of Lundbeck With Buy Rating – Too Cheap to Ignore	FW
05/03	Nordea Resumes Coverage of Lundbeck with Buy Rating and Price Target of 55 Danish Kroner	FW

Business description: H. Lundbeck A/S

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimerâ€™s disease, Bipolar disorder, depression, epilepsy, Huntingtonâ€™s disease, Parkinsonâ€™s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimerâ€™s disease, Azilect for the treatment of Parkinsonâ€™s disease, Xenazine for the treatment of Huntingtonâ€™s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.

Number of employees: 5,039

Sales by Activity: H. Lundbeck A/S

Fiscal Period: December	2021 (DKK)	2022 (DKK)	2023 (DKK)	2024 (DKK)	2025 (DKK)
Research, Development, Production and Sale of Pharmaceuticals	1.63TCr	1.82TCr	1.99TCr	2.2TCr	2.46TCr

See all business segments

Geographical breakdown of sales: H. Lundbeck A/S

Fiscal Period: December	2021 (DKK)	2022 (DKK)	2023 (DKK)	2024 (DKK)	2025 (DKK)
United States	745.6Cr	910.2Cr	982.9Cr	1.13TCr	1.33TCr
Europe	-	425.2Cr	462.8Cr	514.6Cr	581.9Cr
International Operations	415.5Cr	520.3Cr	499.1Cr	521.9Cr	485.8Cr
Unallocated	40Cr	-31Cr	46Cr	31Cr	67Cr
North America (Excl. US)	79Cr	-	-	-	-
Europe (Excl.Denmark)	346.9Cr	-	-	-	-
Denmark	3Cr	-	-	-	-

See all geographic segments

Executive Committee: H. Lundbeck A/S

Manager	Title	Age	Since
Charl van Zyl CEO	Chief Executive Officer	59	01/10/2023
Jörg Hornstein DFI	Director of Finance/CFO	49	01/09/2022
Michala Fischer-Hansen COO	Chief Operating Officer	52	-
Johan Luthman CTO	Chief Tech/Sci/R&D Officer	67	01/03/2019
Thomas Edward Gibbs PRN	Corporate Officer/Principal	55	28/02/2023

See H. LUNDBECK A/S governance

Composition of the Board of Directors: H. Lundbeck A/S

Director	Title	Age	Since
Lene Skole-Sørensen BRD	Director/Board Member	66	25/03/2015
Lars Erik Holmqvist BRD	Director/Board Member	66	25/03/2015
Jeffrey Berkowitz BRD	Director/Board Member	60	20/03/2018
Dorothea Wenzel CHM	Chairman	57	26/03/2025
Santiago Arroyo BRD	Director/Board Member	66	23/03/2021
Camilla Andersson BRD	Director/Board Member	54	01/01/2022
Hossein Armandi BRD	Director/Board Member	64	01/01/2022
Dorte Clausen BRD	Director/Board Member	42	01/01/2022
Lasse Skibsbye BRD	Director/Board Member	43	01/01/2022
Jakob Riis BRD	Director/Board Member	59	01/01/2023

Composition of the Board of Directors

Shareholders: H. Lundbeck A/S

Name	Equities	%	Valuation
Lundbeckfonden 66 %	52,57,51,306	66 %	3 528 M kr
Skagen AS 0.5321 %	42,39,000	0.5321 %	28 M kr
Sector Gamma AS 0.2552 %	20,33,195	0.2552 %	14 M kr
BNP Paribas Asset Management Belgium SA 0.2413 %	19,21,907	0.2413 %	13 M kr
Eika Kapitalforvaltning AS 0.1656 %	13,19,047	0.1656 %	9 M kr

Name	Equities	%	Valuation
Lundbeckfonden 80 %	15,93,18,578	80 %	935 M kr
Nykredit Bank A/S (Investment Management) 0.601 %	11,96,906	0.601 %	7 M kr
Sparinvest SA (Denmark) 0.1607 %	3,20,004	0.1607 %	2 M kr
Equinor Asset Management ASA 0.0527 %	1,05,000	0.0527 %	616 397 kr
Niche Asset Management Ltd. 0.0461 %	91,744	0.0461 %	538 579 kr

List of H. LUNDBECK A/S shareholders

Company details: H. Lundbeck A/S

H. Lundbeck A/S

Ottiliavej 9

2500, Valby

+45 36 30 13 11

http://www.lundbeck.com

Pharmaceuticals Wholesale

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
H. LUNDBECK A/S	-1.51%	-1.56%	-4.55%	+27.21%	576.05Cr
MCKESSON CORPORATION	-1.30%	-5.66%	+43.72%	+165.94%	11TCr
CARDINAL HEALTH, INC.	+0.81%	-4.12%	+70.92%	+189.60%	5.08TCr
SIGMA HEALTHCARE LIMITED	+1.79%	-3.06%	-1.38%	-	2.25TCr
HUADONG MEDICINE CO., LTD	+3.46%	-2.10%	+1.77%	-23.94%	858.51Cr
SINOPHARM GROUP CO. LTD.	-0.29%	-3.19%	+4.98%	-5.23%	827.23Cr
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+0.65%	-0.46%	-10.03%	-12.86%	822.06Cr
GALENICA AG	+0.21%	-1.42%	+13.82%	+27.14%	593.32Cr
MEDIPAL HOLDINGS CORPORATION	-0.24%	-2.30%	+29.67%	+62.00%	381.96Cr
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+1.74%	0.00%	+4.78%	-3.18%	374.1Cr
Average	+0.53%	-1.50%	+15.37%	+47.41%	2.32TCr
Weighted average by Cap.	-0.16%	-0.90%	+37.64%	+137.43%